Although management of multiple myeloma has changed substantially in the last decade, it is unknown whether the burden of ESRD due to multiple myeloma has changed, or whether survival of patients with multiple myeloma on RRT has improved. Regarding ESRD due to multiple myeloma necessitating RRT in the United States, we evaluated temporal trends between 2001 and 2010 for demography-adjusted incidence ratios, relative to rates in [2001][2002], and mortality hazards from RRT initiation, relative to hazards in [2001][2002]. In this retrospective cohort study, we used the US Renal Data System database (n=1,069,343), 2001-2010, to identify patients with ESRD due to multiple myeloma treated with RRT (n=12,703). Demography-adjusted incidence ratios of ESRD from multiple myeloma decreased between 2001-2002 and 2009-2010 in the overall population (demography-adjusted incidence ratio 0.82; 95% confidence interval, 0.79 to 0.86) and in most demographic subgroups examined. Mortality rates were 86.7, 41.4, and 34.4 per 100 person-years in the first 3 years of RRT, respectively, compared with 32.3, 20.6, and 21.3 in matched controls without multiple myeloma. Unadjusted mortality hazards ratios declined monotonically after 2004 to a value of 0.72; 95% confidence interval, 0.67 to 0.77 in 2009-2010, and declines between 2001-2002 and 2008-2009 were observed (P,0.05) in most demographic subgroups examined. Findings were similar when adjustment was made for demographic characteristics, comorbidity markers, and laboratory test values. These data suggest the incidence of RRT from multiple myeloma in the United States has decreased in the last decade, and clinically meaningful increases in survival have occurred for these patients.
ESRD is a feared complication of multiple myeloma, which is reported to be the most common malignancy leading to ESRD. 1 In this regard, the therapeutic approach to earlier-stage multiple myeloma has changed substantially in recent decades. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] However, the current belief is that even with aggressive therapy, the risk of progression to ESRD is high, recovery of renal function is low, and survival time on dialysis therapy is very short. 12 As the detection and treatment of multiple myeloma continues to evolve, it seems natural to question whether reductions in associated ESRD have occurred, and if so, among which demographic subgroups. Surprisingly few, if any, national-level clinical epidemiologic studies of ESRD due to multiple myeloma are available. Hence, we describe the clinical epidemiology of , and black ethnicity/ race (2641 cases; 6.3 PMPY). The demography-adjusted incidence ratio (AIR) for ESRD due to multiple myeloma was lower for patients aged ,40 years (0.06; 95% confidence interval [95% CI], 0.06 to 0.07 versus 40-64 years) and of other ethnicity/ race (0.77; 95% CI, 0.71 to 0.83 versus white). The AIR was higher for patients aged $65 years (4.99; 95% CI, 4.86 to 5.12 versus 40-64 years), of male sex (1.6; 95% CI, 1.56 to 1.64 versus female), and of non-Hispanic black ethnicity/race (2.45; 95% CI, 2.37 to 2.52 versus white). The AIR decreased (P,0.05) between 2001-2002 and 2009-2010 in the overall population (0.82; 95% CI, 0.79 to 0.86) and in all subgroups examined, except age ,40 years, and Hispanic and other ethnicity/race. Table 2 shows baseline characteristics of patients with multiple myeloma requiring RRT at dialysis initiation compared with characteristics of patients with ESRD due to all other causes. More patients with multiple myeloma were aged $65 years (63.6% versus 48.9%), white (76.4% versus 65.4%), and nonHispanic (93.6% versus 86.5%). After adjustment for baseline demographics, characteristics associated with multiple myeloma as cause of ESRD included: older age; non-Hispanic ethnicity; lack of ischemic heart disease and diabetes; hemodialysis for RRT; vascular access other than fistula for hemodialysis; shorter duration of nephrologist care; and lower eGFR, body mass index, serum albumin, and hemoglobin levels. Adjusted odds ratios (AOR) for multiple myeloma as cause of ESRD were notably higher for groups characterized by age $65 years (AOR, ). Patients with multiple myeloma as the cause of ESRD were more likely to die during their follow-up period; a total of 86.6% died (mean follow-up period, 1.6 years), compared with 62.1% of those with ESRD due to other causes (mean follow-up period, 3.4 years; P,0.001). Survival after initiation of RRT for patients with ESRD due to multiple myeloma was significantly worse than for patients with ESRD due to other causes at initiation (Figure 1) .
Causes of death were distributed differently for patients with and without multiple myeloma (P,0.001). In patients with multiple myeloma, the top reported causes of death (versus patients without multiple myeloma) were malignant disease (34.3% versus 2.8%), cardiac arrest (18.5% versus 29.1%), infection (8.3% versus 6.6%), and withdrawal of RRT (8.2% versus 9.7%). Mortality rates in patients with multiple myeloma (Figure 2 ) were 86.7, 41.4, and 34.4 per 100 person-years in the first 3 years of RRT, compared with 32.3, 20.6, and 21.3, respectively, in matched controls without multiple myeloma; Table 4 shows factors associated with mortality, other than year of RRT initiation, for patients with ESRD due to multiple myeloma. Factors associated with mortality (model 1) included: age 40-64 years, age $65 years, white race, non-Hispanic ethnicity, ischemic heart disease, diabetes, hemodialysis as mode of RRT, access other than fistula for RRT, shorter duration of nephrologist care, body mass index ,30 kg/m 2 , hemoglobin ,9.0 g/dL, and serum albumin ,3.5 g/dL. Associations were largely similar after adjustment for baseline demography (model 2) and after full adjustment (model 3). The corresponding overall hazard ratio for death adjusted for baseline demography (AHR) in patients with ESRD due to multiple myeloma versus those with ESRD due to all other causes was 2.05 (95% CI, 1.99 to 2.11; P,0.001). Hazard ratios for death were highest in the first year following RRT initiation (AHR, 2.6; 95% CI, 2.53 to 2.75; P,0.001), and decreased in year 3 (AHR, 1.59; 95% CI, 1.45 to 1.73; P,0.001). Additional characteristics are shown in Supplemental Table 1 . 13 As in our study, patients with multiple myeloma were disproportionately older, male, and white, and proportions of comorbid conditions were more similar to proportions in the general population than to the recognized burden in prevalent ESRD patients. 14 The mortality rate in that study was much higher in patients with than without multiple myeloma; however, temporal trends, incidence ratios, and mortality on RRT were not reported.
The introduction and use of novel agents, including thalidomide, bortezomib, lenalidomide, and carfilzomib, have led to a more targeted approach to therapy and to a trend toward use at earlier disease stages. Widespread integration of these agents into contemporary treatment regimens has demonstrated improvement in both progression-free survival and overall survival. [15] [16] [17] [18] [19] [20] Thus, it is tempting to speculate that the salutary trends in the management and outlook of multiple myeloma include effects on kidney disease; however, true cause-effect relationships cannot be determined in our study due to its observational nature.
The population-level clinical epidemiology of multiple myeloma may be worth considering. 15, [21] [22] [23] In aggregate, it appears that while the incidence of multiple myeloma is rising, mortality rates are dropping. Because our study used aggregate population estimates, the issue of competing risks between non-renal death and ESRD could not be addressed. If the longer survival of patients with multiple myeloma were through non-renal effects, one might expect a rising incidence of ESRD from multiple myeloma.
Interestingly, we demonstrate a more than two-fold higher incidence of ESRD due to multiple myeloma in black versus white patients (Table 1 ; incidence ratio 2.15), but a lower hazard of death compared with white patients in both unadjusted Patients were matched by age, sex, race, ethnicity, and year of RRT inception. Matching occurred for 12,654 of 12,703 patients with multiple myeloma (99.6%). Subgroups are reported by year of RRT initiation (five 2-year periods), age (three levels), sex, and race/ ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, and other). AA, African American; RE, race/ethnicity. and adjusted models (Table 4) . These results mirror recent findings from a Surveillance, Epidemiology, and End Results Program study, in which survival rates in black patients with multiple myeloma were significantly higher than in white patients. 24 This survival benefit is likely not entirely explained by improved dialysis survival among black versus white patients, suggesting disease heterogeneity by race, as African Americans are less likely to undergo autologous stem cell transplant or to receive chemotherapy than other races. [25] [26] [27] As secular trends in survival demonstrate a more pronounced improvement in white than in black patients with multiple myeloma, genetic factors, variable treatment response, or perhaps an indolent disease subtype may be among possible reasons that differences exist. 28 Recent studies support this concept, as cytogenetic differences in black patients with multiple myeloma suggest a higher prevalence of the trisomic form with better response to treatment; however, further study is needed. 28, 29 Although mortality trends for the dialysis patients in our study were similar to those for the general population, the rapid improvement in survival over a 10-year period appears noteworthy. Recent Surveillance, Epidemiology, and End Results Program data demonstrate overall improvement in 5-year survival of 29.6% in 1990 to 44.9% in 2010. 30 Commensurate with these findings, our data demonstrate both a decrease in the demography-adjusted incidence of ESRD due to multiple myeloma, and in mortality rates in the ESRD subset.
Our study has several limitations, including a retrospective registry-based design and a lack of precise information on renal and bone marrow pathology, markers of disease severity, and medications before and after RRT initiation. Moreover, as our data include all patients with multiple myeloma as cause of ESRD, detailed information regarding outcome associations in patients with newly diagnosed versus relapsed or refractory disease cannot be determined. In addition, we lack information on treatment histories and current therapies. Given the crosssectional nature of the data, we were unable to ascertain a trajectory of decline leading to initiation of RRT, as the eGFR values were at the time of RRT initiation. In addition, interpretation should be cautious regarding metrics of ESRD care, such as vascular access other than catheter at RRT initiation and duration of nephrology care before RRT initiation, as need for RRT may be the myeloma-defining event. While a prospective longitudinal design with follow-up starting at first diagnosis of multiple myeloma, and regular, scheduled assessments of renal function would be desirable to determine whether the rates of progression to ESRD have truly changed for the better, such a study would be difficult to eventuate. As need for RRT was used as a surrogate for ESRD in this study, the proportion of patients with true ESRD who elected not to receive RRTor withdrew from RRTafter initiation is unknown. Our findings also do not reflect patients with AKI requiring RRT, with subsequent recovery, or patients who did not survive the requisite 90 days after the date of RRT initiation for Medicare to defray treatment costs. Howell et al. recently demonstrated that referral to palliative care is significantly higher among patients with multiple myeloma than among patients with other hematologic malignancies (odds ratio, 1.96; 95% CI, 1.15 to 3.35). 31 Although relatively small in size and limited to the United Kingdom, this study illustrates contemporary approaches to disease and palliative measures in this patient population. Finally, while it is appealing to posit that therapeutic advances account for the findings of our study, studies with experimental designs with ESRD as primary outcome would be required for confirmation. In spite of its limitations, we believe that this study provides some useful information. Though research efforts to develop alternative efficacious treatments with fewer side effects are clearly needed, it is encouraging that the risk of ESRD caused by multiple myeloma which then requires RRT appears to be declining, and survival lengthening. While developing mechanism-based targeted treatments are of fundamental importance, findings such as associations between ethnicity, lack of pre-RRT care, temporary dialysis access, and mortality suggest that configuration of nephrology care could also be important in patients with multiple myeloma.
CONCISE METHODS

Objectives
Regarding ESRD due to multiple myeloma necessitating RRT in the United States, this study had two major objectives, namely to evaluate 
Statistical Analyses
Data from the United States census were used for population denominators for the years examined, with age in 5-year increments and race/ethnicity classified as non-Hispanic white, non-Hispanic black, Hispanic, and other. Poisson regressionwas used to calculate populationbased incidence ratios of ESRD from multiple myeloma. Chi-squared analysis was used for unadjusted comparisons of patients with and without ESRD due to multiple myeloma, and logistic regression was used for adjusted comparisons. For comparisons of death rates of patients with and without multiple myeloma, patients were matched according to year of dialysis initiation, age (in 1-year intervals), sex, race, and Hispanic ethnicity. Poisson regression was used to compute incidence rates and proportional hazards regression to compute adjusted hazards ratios for death after dialysis initiation, with follow-up ending on June 30, 2012. SAS software, version 9.1.3 (SAS Institute, Cary, NC) was used for data analysis.
